Curated Information

Javascript is not enabled on this browser. This site will not work properly without Javascript.

Home

Curated Information Page

PubMed Id: 18234969

This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus^®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus^®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus^® and may be incomplete.

Reznik TE, et al. (2008) Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res 6, 139-50 18234969

Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.

Y869-p - EGFR (human)

▲

Orthologous residues

EGFR (human): Y869‑p, EGFR (mouse): Y871‑p, EGFR (rat): Y870‑p, EGFR (pig): Y869‑p

Characterization

Methods used to characterize site in vivo: phospho-antibody, western blotting

Disease tissue studied: brain cancer, glioblastoma, glioblastoma multiforme, glioma

Relevant cell lines - cell types - tissues: SNB-19 (glial), U373 MG (glial)

Cellular systems studied: cell lines

Species studied: human

Upstream Regulation

Treatments, proteins and their effect on site modification:

Treatments	Referenced Treatments	Effect	Notes
HGF		increase
actinomycin D	HGF	inhibit treatment-induced increase
cycloheximide	HGF	inhibit treatment-induced increase
PHA-665752	HGF	inhibit treatment-induced increase
siRNA	HGF	inhibit treatment-induced increase	TGF-alpha
	HGF	inhibit treatment-induced increase	CRM197
		decrease	CRM197

Y1092-p - EGFR (human)

▲